MX2022016454A - Compuestos macrociclicos y metodos de uso de los mismos. - Google Patents

Compuestos macrociclicos y metodos de uso de los mismos.

Info

Publication number
MX2022016454A
MX2022016454A MX2022016454A MX2022016454A MX2022016454A MX 2022016454 A MX2022016454 A MX 2022016454A MX 2022016454 A MX2022016454 A MX 2022016454A MX 2022016454 A MX2022016454 A MX 2022016454A MX 2022016454 A MX2022016454 A MX 2022016454A
Authority
MX
Mexico
Prior art keywords
macrocyclic
methods
binding motif
macrocyclic compounds
eulbm
Prior art date
Application number
MX2022016454A
Other languages
English (en)
Inventor
Hao Wu
Jakob Fuhrmann
Wayne Fairbrother
Jeremy Murray
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022016454A publication Critical patent/MX2022016454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se proveen compuestos macrocíclicos que comprenden un motivo de unión a la ubiquitina ligasa E3 (EULBM) y al menos un aminoácido, y métodos para preparar y usar tales EULBM macrocíclicos para el tratamiento del cáncer o de una condición fibrótica. También se proveen inductores químicos heterobifuncionales macrocíclicos de degradación (CIDE) que comprenden un motivo de unión a la ubiquitina ligasa E3 (EULBM) y un motivo de unión a la proteína diana (TPBM) unidos por al menos un aminoácido.
MX2022016454A 2020-06-23 2021-06-22 Compuestos macrociclicos y metodos de uso de los mismos. MX2022016454A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043071P 2020-06-23 2020-06-23
PCT/US2021/038503 WO2021262731A2 (en) 2020-06-23 2021-06-22 Macrocyclic compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022016454A true MX2022016454A (es) 2023-03-06

Family

ID=77207221

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016454A MX2022016454A (es) 2020-06-23 2021-06-22 Compuestos macrociclicos y metodos de uso de los mismos.

Country Status (17)

Country Link
US (1) US20220106361A1 (es)
EP (1) EP4168121A2 (es)
JP (1) JP2023532233A (es)
KR (1) KR20230026461A (es)
CN (1) CN115702026A (es)
AR (1) AR122707A1 (es)
AU (1) AU2021297799A1 (es)
BR (1) BR112022026364A2 (es)
CA (1) CA3185149A1 (es)
CL (2) CL2022003643A1 (es)
CO (1) CO2022018532A2 (es)
CR (1) CR20220658A (es)
IL (1) IL299163A (es)
MX (1) MX2022016454A (es)
PE (1) PE20230617A1 (es)
TW (1) TW202219056A (es)
WO (1) WO2021262731A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024020159A1 (en) * 2022-07-21 2024-01-25 Merck Sharp & Dohme Llc Macrocyclic peptides targeting kras

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144233A (en) 1977-02-16 1979-03-13 The Dow Chemical Company Method for preparing benzo-(1,3,4)-benzotriazepines
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
ES2233070T3 (es) * 1998-08-20 2005-06-01 ELI LILLY & COMPANY Sintesis de analogos peptidicos ciclicos modificados en el anillo.
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
ES2563057T3 (es) 2009-11-05 2016-03-10 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ME02356B (me) 2009-11-05 2016-06-20 Glaxosmithkline Llc Inhibitor bromodomena benzodiazepina
PT2571503E (pt) 2010-05-14 2015-04-29 Dana Farber Cancer Inst Inc Composições e a sua utilização no tratamento de neoplasia, doença inflamatória e outros distúrbios
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
CA2996245C (en) 2015-09-02 2023-10-17 Glaxosmithkline Intellectual Property (No.2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
CN112119085A (zh) * 2017-12-15 2020-12-22 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解

Also Published As

Publication number Publication date
CR20220658A (es) 2023-04-26
WO2021262731A3 (en) 2022-02-24
KR20230026461A (ko) 2023-02-24
TW202219056A (zh) 2022-05-16
BR112022026364A2 (pt) 2023-01-17
AR122707A1 (es) 2022-09-28
JP2023532233A (ja) 2023-07-27
WO2021262731A2 (en) 2021-12-30
CL2022003643A1 (es) 2023-05-26
AU2021297799A1 (en) 2022-12-22
IL299163A (en) 2023-02-01
US20220106361A1 (en) 2022-04-07
CA3185149A1 (en) 2021-12-30
PE20230617A1 (es) 2023-04-14
EP4168121A2 (en) 2023-04-26
CN115702026A (zh) 2023-02-14
CO2022018532A2 (es) 2022-12-30
CL2023002555A1 (es) 2024-01-26

Similar Documents

Publication Publication Date Title
WO2020123300A3 (en) Kras variant mrna molecules
EP4302826A3 (en) Glucagon-like peptide 1 receptor agonists
BR0212203A (pt) Composições e processos para tratamento de diabetes
EA200801309A1 (ru) ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
DK1692158T3 (da) VEGF-binding og understøttede peptider til behandling af hudsygdomme
MX2022015732A (es) Compuestos dirigidos a brm y métodos asociados de uso.
EA202192636A1 (ru) Композиции и способы, содержащие гидовую рнк ttr и полинуклеотид, кодирующий днк-связывающий агент, гидируемый рнк
UA88638C2 (ru) Бета-карболины, полезные для лечения воспалительного заболевания
MX2022016454A (es) Compuestos macrociclicos y metodos de uso de los mismos.
MX2022003930A (es) Conjugados de péptido de camptotecina.
EA202092540A1 (ru) Комбинации для лечения рака
EP4219720A3 (en) Engineered cascade components and cascade complexes
WO2019032936A8 (en) LINCONSAMIDE ANTIBIOTICS AND USES THEREOF
MX2022011958A (es) Conjugados de anticuerpo degradador y métodos de uso de los mismos.
MX2023005301A (es) Compuestos dirigidos a brm y metodos de uso asociados.
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2021178960A3 (en) Compositions and methods for treatment of cancer
MX2023005530A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.
EP4124664A4 (en) PROCESS FOR MANUFACTURING LEATHER WITHOUT TANNING AGENT
EP3826629A4 (en) METHODS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF PANCREATIC CANCER USING 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID
DE60312988D1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
ZA202304030B (en) Modified cxcl10 for immunotherapy of cancer diseases
MX2021013117A (es) Composiciones y metodos para el tratamiento del cancer.
WO2021062389A3 (en) Peptide for treating cancer